Clinical characteristics of liver disease patients with positive anti SLA antibody

Abstract

Abstract: Objective Anti SLA antibody is a specific serological marker of AIH. This study retrospectively evaluated the detection rate of anti SLA in AIH and various liver diseases, and analyzed the clinical characteristics, IAIHG-AIH score, treatment response and outcome of patients with anti SLA positive AIH. Methods Serum anti SLA was detected in 853 patients with liver diseases of different etiology. The presence of anti SLA was detected by Western blot. We recorded the general characteristics and test results of the patients. Results Anti SLA was detected in 18 (2%) of 853 liver disease patients. There were 11 cases of AIH (61.1%), 3 cases of AIH / PBC (16.7%), 2 cases of PBC (11.1%), 1 case of HBV (5.6%) and 1 case of DILI (5.6%). The detection rate of anti SLA in AIH patients was 6%. 11 patients with anti SLA positive AIH received immunosuppressive therapy and developed biochemical remission, but 6 of them relapsed (5 recurred after drug withdrawal and 1 relapsed in remission stage). Conclusion The detection rate of anti SLA is very low, but it has high specificity for AIH. Further studies are needed to prove the clinical significance of anti SLA in AIH.

Key words: Autoantibodies, Autoimmune hepatitis, Liver disease

ZHONG Yan-dan, YU Hai-ying, GUO Yin-yan, DING Qiao-yun, CAO Xing-guo, PENG Shan-shan, YANG Yong-feng. Clinical characteristics of liver disease patients with positive anti SLA antibody[J]. Chinese Hepatolgy, 2021, 26(7): 795-798.

References

[1] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51: 2193-2213.
[2] Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 2008, 48: 169-176.
[3] Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci, 2011, 56: 545-554.
[4] Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology, 2002, 35: 658-664.
[5] Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology, 1998, 28: 296-301.
[6] Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol, 2010, 52: 745-758.
[7] Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology, 2010, 51: 660-678.
[8] Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol, 2010, 53: 372-384.
[9] Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology, 2008, 47: 2089-2111.
[10] Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther, 2010, 32: 3-13.
[11] Manns M, Gerken G, Kyratsoulis A, et al. Characterization of a new subgroup of autoimmune chronic active hepatitis by auto-antibodies against a soluble liver antigen. Lancet, 1987, I: 292–294.
[12] Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut, 2002, 51: 259-264.
[13] Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun, 2003, 21: 77-82.
[14] Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol, 2000, 33: 208-215.
[15] Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet, 2000, 355: 1510-1515.
[16] Eyraud V, Chazouilleres O, Ballot E, et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int, 2009, 29: 857-864.
[17] Vitozzi S, Djilali-Saiah I, Lapierre P, et al. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity, 2002, 35: 485-492.
[18] Duclos-Vallée JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut, 2003, 52: 893-897.